- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00012194
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
Phase I Dose Escalation Study of UCN-01 (NSC 638850) Plus Cisplatin in Advanced Malignant Solid Tumors
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) of cisplatin in combination with UCN-01 in patients with advanced malignancies.
II. To assess the toxicity and observe the potential antitumor activity of UCN-01 plus cisplatin in advanced malignancies at each dose level studies.
III. To determine the pharmacokinetics of UCN-01 and cisplatin on this treatment schedule.
IV. To perform laboratory correlative studies to investigate intermediate molecular markers of the activity of UCN-01 and cisplatin at the cellular level.
OUTLINE: This is a dose-escalation study of cisplatin.
Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of cisplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed every 2-3 months for at least 1 year.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth Hitchcock Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Advanced or metastatic, histologcally/cytologically confirmed malignant solid tumor, not expected to clinically benefit from standard therapy
- Life expectancy greater than 3 months
- Previous chemotherapy and/or radiotherapy must have been completed at least four weeks (six weeks for prior treatment with mitomycin or nitrosoureas) and patients should have recovered from all toxicities of that therapy before treatment under this protocol
- All patients must have recovered from any surgical procedure
- Serum creatinine must be within the institutional limits of normal and an estimated creatinine clearance of >= 60 ml/min
- Normal bilirubin is required
- SGOT/AST must be less than or equal to 2.5 times the upper limit of institutional normal
- WBC >= 4000/mm^3
- Absolute neutrophil count >= 2000/mm^3
- Platelet count >= 150,000/mm^3
- Patients must have a Karnofsky Performance Status of 60% or greater
- Subjects who are fertile must use a medically acceptable contraceptive throughout the treatment period and for three months following cessation of treatment; subjects must be made aware, before entering this trial, of the risk in becoming pregnant or in fathering children
- A signed informed consent (approved by the IRB) must be obtained prior to trial entry
- Tumor site accessible for both pre-treatment and post-treatment biopsy is preferred during dose-finding, and is required for patients entering the expanded cohort at the MTD
- All patients require a central indwelling venous catheter prior to treatment under this protocol
Exclusion Criteria:
- Peripheral neuropathy > grade I
- Any prior mediastinal radiotherapy
- Any history of coronary artery disease
- Class III or IV congestive heart failure according to the New York Heart Classification
- History of allergic reactions to appropriate diuretics or antiemetics (e.g., 5-HT3 antagonists) to be administered in conjunction with protocol directed chemotherapy
- Brain metastasis
- Uncontrolled intercurrent illness that would preclude tolerance and completion of the protocol treatment, including vigorous hydration prior and subsequent to cisplatin therapy
- Lactating or pregnant women are excluded to avoid potential harm to the unborn child or infant; documentation of a negative, serum beta-HCG pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause
- Receipt of any investigational drug within 30 days before beginning treatment with study drug
- Medical, social, or psychological factors that would prevent the patient from completing the treatment protocol
- Patients with clinically significant hearing loss
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Treatment (7-hydroxystaurosporine, cisplatin)
Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Estudos correlativos
Dado IV
Outros nomes:
Dado IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
MTD of cisplatin defined as the highest dose level in which six patients have been evaluated for toxicity with no more than one patient experiencing DLT attributable to the study drugs
Prazo: 4 weeks
|
Graded using the NCI CTCAE.
|
4 weeks
|
Toxicity observed at each dose level, graded using the NCI CTCAE
Prazo: Up to 7 years
|
Summarized in terms of type, severity, time of onset, duration, and reversibility or outcome.
|
Up to 7 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Objective tumor response
Prazo: Up to 7 years
|
Summarized at each dose level, and the number and percent responding combined across dose levels.
|
Up to 7 years
|
Overall survival
Prazo: From registration to time of death due to any cause, assessed up to 7 years
|
Summarized with Kaplan-Meier plots.
|
From registration to time of death due to any cause, assessed up to 7 years
|
Time to treatment failure
Prazo: From registration to the first observation of disease progression, death due to any cause, or early discontinuation of treatment, assessed up to 7 years
|
Summarized with Kaplan-Meier plots.
|
From registration to the first observation of disease progression, death due to any cause, or early discontinuation of treatment, assessed up to 7 years
|
Duration of response
Prazo: Up to 7 years
|
Summarized with Kaplan-Meier plots.
|
Up to 7 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Raymond Perez, Dartmouth-Hitchcock Medical Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NCI-2012-03129
- DMS 9934
- DMS-9934
- NCI-2331
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em análise laboratorial de biomarcadores
-
ORIOL BESTARDConcluídoTransplante Renal | Infecção por CMVEspanha, Bélgica
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Ainda não está recrutandoInfecções por HIV | Hepatite B
-
Bandim Health ProjectResearch Center for Vitamins and Vaccines, Statens Serum InstituteRescindidoMortalidade infantil | BCGGuiné-Bissau
-
McGill University Health Centre/Research Institute...Northwestern UniversityRecrutamentoApnéia da PrematuridadeCanadá
-
Postgraduate Institute of Medical Education and...Desconhecido
-
Riyadh Colleges of Dentistry and PharmacyKing Faisal Specialist Hospital & Research CenterDesconhecidoMucosite Oral